Shield Therapeutics’ (STX) FY20 results reported total revenue of £10.4m reflecting an $11.4m (£9.7m) upfront payment received from ASK Pharm (Feraccru out-licensing deal that covers China) and £0.7m from royalties on Feraccru sales from European partner Norgine. In March 2021, STX raised net funds of £27.8m, which will be utilised to support the US launch and commercialisation of Accrufer (iron deficiency). The focus for STX now is to establish and expand its US-based operations ahead of a Q221 ....
04 May 2021
Shield Therapeutics - 2021 all eyes on Accrufer US launch
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - 2021 all eyes on Accrufer US launch
Shield Therapeutics Plc (STX:LON) | 1.4 0 0.0% | Mkt Cap: 11.1m
- Published:
04 May 2021 -
Author:
Dr Susie Jana -
Pages:
5
Shield Therapeutics’ (STX) FY20 results reported total revenue of £10.4m reflecting an $11.4m (£9.7m) upfront payment received from ASK Pharm (Feraccru out-licensing deal that covers China) and £0.7m from royalties on Feraccru sales from European partner Norgine. In March 2021, STX raised net funds of £27.8m, which will be utilised to support the US launch and commercialisation of Accrufer (iron deficiency). The focus for STX now is to establish and expand its US-based operations ahead of a Q221 ....